Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > CAR-T update

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 09, 2023 10:37pm

170 Views

Post# 35776639

RE:RE:RE:CAR-T update

December 07, 2023 - Supplemental CAR-T work at Mayo Clinic was released recently using an OV which administered systemically before the standard treatment, which typically includes limb amputation and chemotherapy, and paves the way for further investigations into dose modification and combination therapy strategies with CAR-T therapy + OVs for the treatment of sarcomas.

https://phys.org/news/2023-12-viral-treatment-effective-devastating-bone.html

<< Previous

Bullboard Posts

Next >>

Stockhouse DealRoom opens new Australian opportunities